The anti-HER2 monoclonal antibody pertuzumab may be effective in androgen-independent prostate cancer

Clin Prostate Cancer. 2003 Dec;2(3):143-5. doi: 10.1016/s1540-0352(11)70034-8.
No abstract available

MeSH terms

  • Androgen Antagonists / therapeutic use
  • Antibodies, Monoclonal / therapeutic use*
  • Breast Neoplasms / drug therapy
  • Clinical Trials, Phase I as Topic
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prostatic Neoplasms / drug therapy*
  • Receptor, ErbB-2 / immunology
  • Treatment Outcome

Substances

  • Androgen Antagonists
  • Antibodies, Monoclonal
  • Receptor, ErbB-2